Dasatinib (Sprycel®) is a second-generation BCR-ABL inhibitor with improved potency and better inhibitory profiles against the ABL mutants found in CML patients [83]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.